Search

Your search keyword '"PD Dr. Schattenberg Jörn"' showing total 5 results
Start Over Author "PD Dr. Schattenberg Jörn"
5 results on '"PD Dr. Schattenberg Jörn"'

1. PS-058-The socio-economic burden of NASH in Europe and the United States: The gain study

Author

Rosa Willock, Quentin M. Anstee, Anthony Hatswell, Vanessa Hebditch, Mzwandile A. Mabhala, Jamie O'Hara, PD Dr. Schattenberg Jörn, Judy Rhys, Manuel Romero-Gómez, Vlad Ratziu, Gregory Guzauskas, Leonardo Ruiz, Alan Finnegan, Thomas Russell, Bengt Jönsson, Ingo Van Thiel, Elisabetta Bugianesi, Tatjana Reic, and George Morgan

Subjects
Hepatology, Development economics, Economics
Published
2019
Full Text
View/download PDF

2. SAT-067-Prospective assessment of sarcopenia as a prognostic factor for survival in patients with liver cirrhosis

Author

PD Dr. Schattenberg Jörn, WM Kremer, A Grambihler, Anna Christina Koch, Dorothea Lochner, Martin F. Sprinzl, Christian Labenz, Sandra Koch, Christoph Düber, Peter R. Galle, Arndt Weinmann, and Felix Hahn

Subjects
medicine.medical_specialty, Prognostic factor, Cirrhosis, Hepatology, business.industry, Internal medicine, Sarcopenia, medicine, In patient, medicine.disease, business, Gastroenterology
Published
2019
Full Text
View/download PDF

3. SAT-348-Low frequencies of lifestyle interventions and liver-specific medications in a multicentric prospective real world NAFLD cohort: The fatty liver assessment in Germany (FLAG) study

Author

Michael P. Manns, Patrick Ingiliz, K. Stein, Jeannette Schwenzer, PD Dr. Schattenberg Jörn, Wolf Peter Hofmann, Anna Schmidt, Stefan Zeuzem, Marion Muche, Peter Buggisch, Lisa Schubert, Renate Heyne, Frank Lammert, and Nektarios Dikopoulos

Subjects
medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Lifestyle intervention, Cohort, Fatty liver, medicine, FLAG (chemotherapy), business, medicine.disease
Published
2019
Full Text
View/download PDF

4. PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure

Author

Beat Müllhaupt, Matschenz Kathrin, Christoph Antoni, Elena Durmashkina, Christoph Sarrazin, Janina Trauth, PD Dr. Schattenberg Jörn, Tania M. Welzel, Julia Dietz, Thomas Discher, Christoph P. Berg, Claus Niederau, Stefan Zeuzem, Stefan Mauss, Julian Schulze zur Wiesch, Christoph Neumann-Haefelin, Johannes Vermehren, Felix Piecha, Tobias Müller, Thomas Berg, and Peter Buggisch

Subjects
chemistry.chemical_compound, Hepatology, Resistance (ecology), chemistry, business.industry, Genotype, Medicine, NS5A, business, NS5B, Virology, Long term persistence, Treatment failure
Published
2019
Full Text
View/download PDF

5. LBO-02-Elafibranor, a peroxisome proliferator-activted receptor alpha and delta agonist demonstrates favourable efficacy and safety in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid treatment

Author

David Magrez, PD Dr. Schattenberg Jörn, Rémy Hanf, John M. Vierling, S. Megnien, Stephen H. Caldwell, David Jones, MB Bchir, Cynthia Levy, Kris V. Kowdley, Velimir A. Luketic, Daniel Pratt, Pascal Birman, Albert Parés, Alan Bonder, Gideon M. Hirschfield, and Michael A. Heneghan

Subjects
Agonist, Hepatology, Peroxisome proliferator, medicine.drug_class, business.industry, Alpha (ethology), Elafibranor, Pharmacology, Ursodeoxycholic acid, medicine, In patient, business, Receptor, medicine.drug
Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results